Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
Status:
Terminated
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the safety of giving enzalutamide with leuprolide acetate before
and after radiation therapy and to see how well it works in treating patients with prostate
cancer that is at high risk of returning. Radiation therapy uses high-energy x-rays to kill
tumor cells and shrink tumors. Most types of prostate cancer also need testosterone to grow
and spread. After radiation therapy, patients often receive treatments to reduce testosterone
to prevent the cancer from returning. Leuprolide acetate works by reducing the amount of
testosterone that the body makes. Enzalutamide is a stronger treatment that may block
testosterone from reaching cancer cells. Adding enzalutamide to treatment with leuprolide
acetate after radiation therapy may help prevent high-risk prostate cancer from returning and
improve patient survival.